Please login to the form below

Not currently logged in
Email:
Password:

BIIB059

This page shows the latest BIIB059 news and features for those working in and with pharma, biotech and healthcare.

Biogen doses first patient in phase 3 systemic lupus erythematosus study

Biogen doses first patient in phase 3 systemic lupus erythematosus study

Biogen has started dosing patients in a late-stage study evaluating its potential systemic lupus erythematosus (SLE) treatment BIIB059. ... added. In addition to BIIB059, Biogen also has another investigational lupus asset – dapirolizumab pegol –

Latest news

  • Biogen scores mid-stage trial win for lupus drug BIIB059 Biogen scores mid-stage trial win for lupus drug BIIB059

    The SLE arm only tested the highest 450mg dose of BIIB059, and showed the drug reduced the number of joints with active inflammation compared to placebo at 24 weeks. ... We are excited by the LILAC study results, and the potential for BIIB059 to be a

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Five big changes in the healthcare comms landscape
The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....